Jump to top navigation | Jump to main navigation | Jump to content
Therapeutic Goods Administration logo

Australian regulatory guidelines for complementary medicines (ARGCM)

Purpose of ARGCM

The Australian Regulatory Guidelines for Complementary Medicines (ARGCM) have been developed to:

  • provide information to help sponsors of complementary medicines to meet their obligations under therapeutic goods legislation;
  • help ensure that applications to the TGA relating to complementary medicines uniformly meet all essential regulatory requirements so that applications may be processed successfully within minimum timeframes; and
  • enhance clarity and transparency of processes leading to the Registration and Listing of complementary medicines in the Australian Register of Therapeutic Goods (ARTG).

Development of ARGCM

The Therapeutic Goods Administration (TGA), in consultation with the Australian Self-Medication Industry (ASMI) and the Complementary Healthcare Council of Australia (CHC), commenced a project to develop guidelines specifically for Complementary Medicines in August 2001.

A Consultation Group, comprising members from the TGA, ASMI and CHC with experience in the regulation and manufacture of complementary medicines, was established to assist in the development of a draft of the ARGCM for stakeholder consultation.

The content of the ARGCM is intended to reflect the current Australian requirements for the regulation of complementary medicines.

The TGA in consultation with the peak complementary medicines industry associations identified the priorities in developing the individual parts of the ARGCM.

After being drafted by the TGA/Industry Consultative Group, each part underwent stakeholder consultation, was reviewed by the Consultation Group and then revised to address comments received from stakeholders.

Top of page

ARGCM structure and content

The ARGCM is structured in five parts.

  • Part I provides guidance on the Registration of complementary medicines.
  • Part II provides guidance on Listed complementary medicines.
  • Part IIIprovides guidance on the evaluation of complementary medicine substances for use in Listed medicines (that is, for inclusion in Schedule 4 of the Therapeutic Goods Regulations 1990) including new substances, 'switch' substances1 and excipients used in complementary medicines.
  • Part IV provides general guidance in relation to complementary medicine modalities such as homoeopathy, traditional herbal medicine and aromatherapy. This part also provides information on exempt medicines, combination complementary / pharmaceutical medicines and the food / medicine interface and contains a glossary of terms.
  • Part V provides details of TGA policy guidelines relevant to complementary medicines.
  • ARGCM amendment schedule provides details of the changes made to the guidelines.

Wherever possible, the guidelines reflect consistency with, and are drawn from, other TGA guidelines.

To meet the needs of all stakeholders requiring guidance on the regulation of complementary medicines, the ARGCM is structured to provide different levels of detail ranging from broad overviews to, for example, specific technical guidance on the selection and quality of individual studies to support the safety of complementary medicine substances.

1 'Switch' substances are complementary medicine substances that, as active ingredients, are currently included in registered complementary medicines but subject to an application for evaluation as a substance for use in Listed medicines, their status may be 'switched' to Listable. For example, this may be a substance for which the SUSDP restriction has been removed, or one that is currently approved for use as an excipient only.

Top of page

ARGCM Part I - Registration of complementary medicines

Part I of the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) is intended to provide guidance on the requirements for the Registration of complementary medicines.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Contents of ARGCM Part I

  1. Overview
  2. Eligibility for registration
  3. Route of evaluation
  4. The registration process
  5. Administrative information
  6. Quality
  7. Efficacy and safety
  8. Labelling and presentation
  9. Product Information
  10. Consumer Medicine Information
  11. Changes to registered complementary medicines
  12. Post market review
  13. Part I Appendix 1 - Stability of the finished product

Top of page

ARGCM Part II - Listed complementary medicines

Part II of the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) provides guidance on the Listing of medicines in the Australian Register of Therapeutic Goods.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Contents of ARGCM Part II

  1. Overview
  2. Eligibility for including Listed complementary medicines on the ARTG
  3. The Listing process
  4. The Electronic Listing Facility - Version 3 (ELF 3)
  5. Quality
  6. Safety and efficacy
  7. Labelling and presentation
  8. Post market review
  9. Product changes
  10. Other requirements
  11. Appendix 1 - Electronic Listing Facility (ELF) User Guide

Top of page

ARGCM Part III - Evaluation of complementary medicine substances

Part III of the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) is intended to provide guidance on the evaluation of complementary medicine substances for use in listed medicines.

How to access a pdf document

Contents of ARGCM Part III

  1. Overview
  2. Eligibility
  3. Evaluation process
  4. Quality
  5. Safety
  6. Appendices
    1. Part III Appendix 1 Example Format for Draft Compositional Guidelines for Complementary Medicine Substances
    2. Part III Appendix 2 Impurities and Incidental Constituents
    3. Part III Appendix 3 Safety Data Requirements and Suitability

Top of page

ARGCM Part IV - General guidance

Part IV of the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) provides general guidance in relation to complementary medicine modalities such as homoeopathy, traditional herbal medicines and aromatherapy. This part also provides information on exempt medicines, combination complementary / pharmaceutical medicines and the food / medicine interface and contains references and a glossary of terms.

How to access a pdf document

*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Contents of ARGCM Part IV

  1. Overview
  2. Homoeopathic Preparations and Mother Tinctures
  3. Traditional Herbal Medicines
  4. Aromatherapy
  5. Practitioner Products
  6. Exempt / Excluded Goods
  7. Proprietary Ingredients
  8. Interface Issues
  9. Australian Native and Endangered Species in Therapeutic Goods
  10. Other Legislation
  11. Certificates of Analysis - Product
  12. Product Specifications
  13. Enforcement Procedures
  14. Review of Decisions
  15. Genetically Modified Organisms
  16. Medicines for Export
  17. Naming of New Substances and Terminology
  18. Colourings Permitted in Medicines for Oral Use
  19. Herbal Ingredients - Quality
  20. Ingredients of Human or Animal Origin
  21. Glossary of Terms Used in ARGCM
  22. Abbreviations and Acronyms used in the ARGCM
  23. Hyperlink References Contained in the ARGCM

Top of page

ARGCM Part V - Policy documents and guidelines

Part V of the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) provides details of TGA policy guidelines relevant to complementary medicines.

How to access a pdf document

Contents of ARGCM Part V

  1. Overview
  2. Levels and kinds of evidence to support indications and claims
  3. Minimising the risk of Transmissible Spongiform Encephalopathies (TSEs)
  4. Quantified by input
  5. European Union (EU) guidelines referenced in the ARGCM
  6. Section 7 declarations
  7. Confidentiality

Top of page

ARGCM amendment schedule

How to access a pdf document

ARGCM amendment schedule - version 3.3 (March 2006) (pdf,36kb)

Top of page